Click here to see Important Safety Information below 
AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg has been approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
AMPYRA is the first and only MS therapy that has been specifically approved by the FDA to improve walking in people with MS. More than 400,000 people in the U.S. and nearly 2.5 million people worldwide are living with MS1, and for the majority of those people, the disease affects their ability to walk2. Improved walking can have a meaningful impact on the lives of people with MS and their caregivers, and we are gratified to have been able to contribute to advancing the care of people with MS.
For more information, visit www.AMPYRA.com.
Do not take AMPYRA if you have ever had a seizure, or have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.
Take AMPYRA exactly as prescribed by your doctor.
You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50.
Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA.
AMPYRA may cause serious allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.
AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.
The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance.
Before taking AMPYRA tell your doctor if you are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.
Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both.
Please see the full Prescribing Information and Patient Medication Guide.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
1 National Multiple Sclerosis Society website
2 Harris Interactive MS Survey, 2011
AMPYRA® is a registered trademark of Acorda Therapeutics®, Inc. AMPYRA® is marketed by Acorda Therapeutics, Inc. and manufactured under license from Alkermes Pharma Ireland Ltd.